Photo: Solskin/Getty Images
myTomorrows, a company that helps connect patients to clinical trial sites, has secured $29 million from Avego.
WHAT IT DOES
The company helps patients and their families find treatment options in clinical development or awaiting approval. It also helps biopharma companies recruit candidates for clinical trials.
myTomorrows' AI platform helps patients, alongside their physicians, search for available clinical trials and provides relevant medical information to help them determine which options are available.
Patients can review the options and if one pursues an available clinical trial, myTomorrows guides them through the steps to get referred.
The company will use the funds to hasten AI development and strengthen industry alliances.
"This investment marks a pivotal step in our journey to give every patient, no matter where they live, a fair shot at tomorrow's therapies," Michel van Harten, CEO of myTomorrows, said in a statement.
"Avego's extensive expertise in life sciences, particularly BioPharma, will be instrumental as we scale our platform and broaden our impact across the global health landscape."
MARKET SNAPSHOT
In September, myTomorrows announced a new offering aimed at supporting trial site clinical research teams via its AI-powered platform.
The referral management tool works with myTomorrows' in-house patient navigation service and is intended to address barriers in trial awareness, patient recruitment and retention.
In 2024, myTomorrows partnered with the ALS Association.
Through the partnership, the ALS Association gained access to myTomorrows’ database of clinical trials and its patient navigation service.
The aim is to provide physicians and people living with ALS with the latest data about pre-approval treatment options in order to give individuals information about clinical trials that would be a good match.
